From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry ...

In a bid to help the immune system of autoimmune disease patients reset, a San Francisco startup startup has raised $120 ...

Patrizia Cavazzoni, leader of the FDA's Center for Drug Evaluation and Research, is leaving the agency on Jan. 18.

ClearBridge Investments, an investment management company, released its “ClearBridge Growth Strategy” fourth quarter 2024 ...

A new biotech start-up – Ouro Medicines – launched today with $120 million in funding from a Series A and a plan to develop ...

Royalty Pharma will present at the 43rd Annual J.P. Morgan Healthcare Conference at 6:45 p.m. ET / 3:45 p.m. PT on January 14, 2025. The webcast will be accessible from Royalty Pharma's "Events” page ...

In a report released today, Mohit Bansal from Wells Fargo assigned a Hold rating to Biogen (BIIB – Research Report), with a price target of ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

Armed with $115 million and a clinical-stage asset, another player is emerging in the increasingly crowded T cell engager ...

NervGen is engaged in groundbreaking research in spinal cord injury treatment. Read here for an update on the research's ...

Alzheimer’s drugs could unlock a $13 billion market by 2030, with Biogen, Eli Lilly, Novo Nordisk, Roche, and UCB leading the ...